A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
Public ClinicalTrials.gov record NCT07117487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-label Study to Evaluate Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 at Least 12 Months Following a Primary Dose of a Licensed Protein Subunit RSV Vaccine in Adult Participants ≥60 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Study identification
- NCT ID
- NCT07117487
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 507 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2025
- Primary completion
- Mar 26, 2026
- Completion
- Mar 26, 2026
- Last update posted
- May 3, 2026
2025 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Velocity Clinical Research, Denver | Denver | Colorado | 80110 | — |
| Indago Research & Health Center, Inc. | Hialeah | Florida | 33012 | — |
| Velocity Clinical Research, Savannah | Savannah | Georgia | 31406 | — |
| Velocity Clinical Research, Valparaiso | Valparaiso | Indiana | 46383 | — |
| Velocity Clinical Research, Covington | Covington | Louisiana | 70433 | — |
| Velocity Clinical Research, Rockville | Rockville | Maryland | 20854 | — |
| Velocity Clinical Research, Lincoln | Lincoln | Nebraska | 68510 | — |
| Velocity Clinical Research, Medford | Medford | Oregon | 97504 | — |
| Velocity Clinical Research, Austin | Austin | Texas | 78759 | — |
| Velocity Clinical Research, Hampton | Hampton | Virginia | 23666 | — |
| Velocity Clinical Research, Spokane | Spokane | Washington | 99218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07117487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07117487 live on ClinicalTrials.gov.